Key result
Antiarrhythmic drug therapy for atrial fibrillation is evolving to target specific triggers and ion currents, aiming to overcome the limitations and proarrhythmic risks of classical agents.
Future antiarrhythmic drugs for atrial fibrillation will likely target specific atrial ion currents and molecular pathways, remaining a cornerstone therapy complementary to ablation.
No takes yet. Share an insight, caveat, or question.
May guide future AAD selection in AF; leaves open need for randomized validation of targeted agents.
Dan et al. (2018) conducted a review in Atrial fibrillation. Antiarrhythmic drugs was evaluated. Antiarrhythmic drug therapy for atrial fibrillation is evolving to target specific triggers and ion currents, aiming to overcome the limitations and proarrhythmic risks of classical agents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: